Related Experiment Video
Updated: Jun 9, 2026
Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
Published on: November 20, 2015
Postnatal erythropoietin treatment mitigates neural cell loss after systemic prenatal hypoxic-ischemic injury
Marcus Mazur1, Robert H Miller, Shenandoah Robinson
1Department of Neurosurgery, Rainbow Babies & Children's Hospital, Center for Translational Neuroscience, The Neurological Institute of University Hospitals Case Medical Center, Case Western Reserve School of Medicine, Cleveland, Ohio 44106, USA.
Insights
Neonatal administration of recombinant human erythropoietin (rhEPO) after prenatal brain injury in rats rescues neural cells. This treatment improves long-term histological and functional outcomes, offering hope for minimizing neurological deficits in preterm infants.
Area of Science:
- Neuroscience
- Developmental Biology
- Neonatal Medicine
Background:
- Preterm birth-related brain injury leads to severe neurological deficits like cerebral palsy.
- Current treatments are limited as brain injury often begins before birth.
- Erythropoietin (EPO) is a neuroprotective cytokine, but its mechanism in the developing brain is not fully understood.
Purpose of the Study:
- To investigate if prenatal hypoxia-ischemia disrupts EPO signaling in the developing brain.
- To determine if neonatal recombinant human EPO (rhEPO) administration can restore EPO signaling and enhance neural cell survival after prenatal injury.
Main Methods:
- A rat model of prenatal hypoxia-ischemia (HI) was used, mimicking third-trimester placental insufficiency.
- Neonatal rhEPO was administered post-injury, followed by histological, biochemical, and functional analyses.
- The study analyzed effects in neonatal, juvenile, and adult rats.
Main Results:
- Prenatal HI upregulated brain EPO receptors, particularly on oligodendroglial cells and neurons.
- Postnatal rhEPO treatment reduced brain damage and rescued key neural cell populations.
- rhEPO treatment restored myelin basic protein expression and improved motor skills and seizure thresholds in adult rats.
Conclusions:
- Neonatal rhEPO administration effectively rescues neural cells following prenatal hypoxic-ischemic injury in rats.
- This treatment leads to lasting histological and functional improvements in adult animals.
- The findings support rhEPO as a potential postnatal intervention to mitigate chronic neurological deficits.
Object:
Brain injury from preterm birth predisposes children to cerebral palsy, epilepsy, cognitive delay, and behavioral abnormalities. The CNS injury often begins before the early birth, which hinders diagnosis and concurrent treatment. Safe, effective postnatal interventions are urgently needed to minimize these chronic neurological deficits. Erythropoietin (EPO) is a pleiotropic neuroprotective cytokine, but the biological basis of its efficacy in the damaged developing brain remains unclear. Coordinated expression of EPO ligand and receptor expression occurs during CNS development to promote neural cell survival. The authors propose that prenatal third trimester global hypoxia-ischemia disrupts the developmentally regulated expression of neural cell EPO signaling, and predisposes neural cells to death. Furthermore, the authors suggest that neonatal exogenous recombinant human EPO (rhEPO) administration can restore the mismatch of EPO ligand and receptor levels, and enhance neural cell survival.
Methods:
Transient systemic hypoxia-ischemia (TSHI) on embryonic Day 18 in rats mimics human early-third trimester placental insufficiency. This model was used to test the authors' hypothesis using a novel clinically relevant paradigm of prenatal injury on embryonic Day 18, neonatal systemic rhEPO administration initiated 4 days after injury on postnatal Day 1, and histological, biochemical, and functional analyses in neonatal, juvenile, and adult rats.
Results:
The results showed that prenatal TSHI upregulates brain EPO receptors, but not EPO ligand. Sustained EPO receptor upregulation was pronounced on oligodendroglial lineage cells and neurons, neural cell populations particularly prone to loss from CNS injury due to preterm birth. Postnatal rhEPO administration after prenatal TSHI minimized histological damage and rescued oligodendrocytes and gamma-aminobutyric acidergic interneurons. Myelin basic protein expression in adult rats after insult was reduced compared with sham controls, but could be restored to near normal levels by neonatal rhEPO treatment. Erythropoietin-treated TSHI rats performed significantly better than their saline-treated peers as adults in motor skills tests, and showed significant seizure threshold restoration using a pentylenetetrazole increasing-dose paradigm.
Conclusions:
These data demonstrate that neonatal rhEPO administration in a novel clinically relevant paradigm initiated 4 days after a global prenatal hypoxic-ischemic insult in rats rescues neural cells, and induces lasting histological and functional improvement in adult rats.
